Compare McKesson Corporation (MCK) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs SYSCO Corporation — how do they compare? McKesson Corporation trades at $937.1 (market cap $108.46B), while SYSCO Corporation trades at $78.1 (market cap $38.47B). The key difference: McKesson Corporation is far larger — about 2.8× SYSCO Corporation's market cap, and SYSCO Corporation pays the higher dividend (2.81%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and SYSCO Corporation for 77 Days on average.
| MCK | SYY | |
|---|---|---|
Market Cap | $108.46B | $38.47B |
Volume | 712,607 | 4,808,465 |
Sector | Health | Consumer Staples |
52-Week High | $995.69 | $91.16 |
52-Week Low | $725.17 | $69.30 |
Typical Hold Time | 74 Days | 77 Days |
Enterprise Value | $115.00B | $51.65B |
Dividend Yield | 0.4% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $937.98, up 3.04% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent positive developments include the CVS Health partnership extension through 2032 and raised full-year guidance. Revenue growth remains robust at $359.05 billion for 2025, though net margins are thin at 1.12%.
The outlook remains positive with 81% analyst buy ratings and a $956.43 consensus target. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. Strong cash flow generation ($6.09B operating cash flow) supports the dividend and growth initiatives, while technical indicators show the stock testing resistance near $938.
Sysco Corporation (SYY) trades at $78.14, up 1.76% with neutral technical signals. The company maintains steady revenue growth reaching $81.37B in 2025, though net margins compressed to 2.08%. Recent corporate actions include a $1.5B senior notes offering and a $0.55 dividend declaration. Technical indicators show mixed signals with RSI neutral at 49.4 and ADX suggesting weak trend direction. The stock trades below analyst consensus target of $85.75 with 60% buy ratings.
Sysco presents a balanced investment case with attractive valuation metrics (P/S 0.44) and strong institutional support, offset by margin pressure and elevated debt levels. The AI efficiency program targeting $500M savings by 2029 provides growth catalyst potential. Key risks include competitive pressures in food distribution and sensitivity to economic cycles affecting restaurant demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
